SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Amgen Inc. (AMGN)
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
1906 112 0 AMGN
Emcee:  trevor john wilkinson Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1406>>Amgen Announces Update To U.S. Prescribing Information for Aranesp(R) antuck-3/9/2007
1405Doesn't matter that my cost basis is about a dollar, folks. Amgen is a sizJGoren-3/8/2007
1404Goren is used to making 6000% at the bridge table every year.tom pope-3/8/2007
1403I wonder how they will perceive your email since the average cost of your 1989 sQualified Opinion-3/8/2007
1402email sent to investor relations: Dear Sirs: For the past six years, I have haJGoren-3/8/2007
1401gs = goldman sachsmopgcw-3/8/2007
1400I don't see any attribution of where the last two analyst reports came from.JGoren-3/8/2007
1399gs: Amgen Inc. (AMGN): Update on anemia and FDA discussions. Reiterated guidancemopgcw-3/8/2007
1398gs: Amgen Inc. (AMGN): Improving risk reward but expect further volatility 52-Wmopgcw-3/8/2007
1397GS: Amgen Inc. (AMGN): One Medicare carrier dropped Aranesp in anemia of cancer mopgcw-3/8/2007
1396Amgen: It Keeps Getting Worse MORGAN STANLEY RESEARCH 2007-02-28 22:47 (New Yorkmopgcw-3/8/2007
1395FBR notes that tomorrow, the generic biologic debate begins in earnest and Amgenjad-3/7/2007
1394CS on Amgen: >>Amgen Upgraded to "Neutral" on Value Monday Marctuck-3/6/2007
1393FWIW, Lehman on Amgen Inc (AMGN): ODAC Meeting Not a Threat: Deja Vu Sector Ratijad-3/2/2007
1392Thanks Tom. But that is what I don't get. I thought the nsclc trail was keokalani'nui-3/1/2007
1391Based on conversations with doctors, we believe Aranesp use is already decliningtom pope-3/1/2007
1390Do they get specific in that report about the % aranesp use in patients above thkeokalani'nui-3/1/2007
1389ML says to wait, Tuck - on a worst case basis: Worst Case of $48; Probability Atom pope-3/1/2007
1388But WHY is the SEC also involved with investigating the Danish study?steve kammerer-3/1/2007
1387>>Amgen to Participate in Oncologic Drugs Advisory Committee in May Wednestuck-3/1/2007
1386Forbes: Amgen's Latest Mess Matthew Herper and Robert Langreth 02.16.07, 7:5mopgcw-2/25/2007
1385>>Roche suspends enrollment in anemia drug trial Fri Feb 23, 2007 3:09pm Etuck-2/23/2007
1384<i>why studies so far outside the labeling?</i> To test the hypotheDewDiligence_on_SI-2/20/2007
1383why studies so far outside the labeling?JGoren-2/20/2007
1382Amgen: Buying opportunity! Couple of firms are out in defense of Amgen (NASDAQ:Ajad-2/20/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News